Navigation Links
InterMune Announces Closing of Public Offering of Common Stock
Date:9/26/2007

BRISBANE, Calif., Sept. 26 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: ITMN) today announced that it closed its public offering of 4,025,000 shares of common stock at a price to the public of $19.50 per share, including 525,000 shares of common stock, representing the exercise by the underwriters of their option to purchase additional shares in the offering. The net proceeds to the company of the offering are approximately $73.8 million, after payment of underwriting discounts and commissions, but excluding estimated offering expenses.

Goldman, Sachs & Co. acted as the sole book-running manager of the offering. Deutsche Bank Securities Inc. acted as co-lead manager and CIBC World Markets Corp. acted as co-manager of the offering.

These shares were issued pursuant to an effective shelf registration statement. This press release shall not constitute an offer to sell or a solicitation of an offer to buy nor will there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. The offering of common stock was made only by means of a prospectus, including a prospectus supplement, forming a part of the effective registration statement. Printed copies of the final prospectus supplement and base prospectus relating to the offering may be obtained from Goldman, Sachs & Co. (Attn: Prospectus Department, 85 Broad Street, New York, New York 10004, Fax: 212-902-9316 or Email at prospectus-ny@ny.email.gs.com). A prospectus supplement relating to the offering has been filed with the SEC, and is available along with the base prospectus filed with the SEC in connection with the shelf registration, on the SEC's website at http://www.sec.gov/.

About InterMune

InterMune is a biotechnology company focused on the research, development and commercialization of innovative therapies in pulmonology and hepatology.


'/>"/>
SOURCE InterMune, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Speaker announces business members of IT Task Force
2. Doyle announces technology tax credits for Berbee
3. Doyle announces new energy, global warming policies
4. Doyle announces $80M renewable energy strategy
5. GE announces first installation of Discovery VCT
6. UWM announces winners of RGI awards
7. Third Wave announces two senior management appointments
8. Mirus announces new method for making antibodies
9. Merge announces sofware updates, upcoming acquisition
10. Small Tree announces ethernet solution for Apple Xserv G5
11. TEKLYNX International announces new RFID software
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/12/2020)... ... 12, 2020 , ... Inc. magazine today revealed that ... compliance consulting has been named on its annual Inc. 5000 list, the most ... look at the most successful companies within the American economy’s most dynamic segment—its ...
(Date:8/3/2020)... ... August 03, 2020 , ... Introducing Ardent Animal Health – MediVet Biologics rebrands ... , Known as MediVet Biologics since its formation in 2016, the company is ... Animal Health will build on its base of innovative therapies for osteoarthritis and cancer. ...
(Date:7/31/2020)... ... July 29, 2020 , ... ... radar transmitter systems that can be configured to drive Klystrons, TWTs, IOTs, and ... can drive one or two switches in a push-pull configuration; yielding fast fall ...
(Date:7/31/2020)... ... ... eSource has long been touted as the solution to high data management ... reasons it did not take off as quickly as people initially expected, and where ... towards capturing data electronically for clinical trials and then repurposing it for downstream analysis, ...
Breaking Biology Technology:
(Date:6/23/2020)... ... June 23, 2020 , ... First Aid Africa, ... a UK supplier and manufacturer of innovative portable renewable energy equipment, have announced ... fight against the COVID-19 pandemic in Zambia. , One of Renovagen’s FAST FOLD ...
(Date:6/23/2020)... ... June 23, 2020 , ... Rigaku Corporation ... next event in a series of TOPIQ webinars, which will cover the Transferable ... was developed in response to social distancing measures that resulted in postponements and ...
(Date:6/19/2020)... , ... June 16, 2020 , ... The director of ... betting that if the stem cell medicine and pharmaceutical industries have easier access to ... So, starting July 5 of this year, Independence Day weekend in the U.S., ...
Breaking Biology News(10 mins):